
    
      This trial is a single-center, prospective phase II clinical study, which mainly evaluates
      the efficacy and safety of first-line treatment with pembrolizumab combined with chemotherapy
      in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    
  